![]() 179/04 on the file of the Hon'ble Court of the Principal Sub Judge, Palakkadġ8. S T C No: 338/06 on the file of the Hon'ble Court of the Hon'ble Court of the Judicial First Class Magistrate – VII, Thiruvananthapuramġ7. Appeal no: 618/05 on the file of the Hon'ble Court of the Hon'ble Court of the Addl. 114/01 on the file of the Hon'ble Court of the Judicial First Class Magistrate - I, Palakkadġ5. ![]() ![]() 398/07 on the file of the Hon'ble Court of the Ist Additional Sub Judge, Thiruvananthapuramġ4. 1468/2000 on the file of the Hon'ble Court of the Ist Addl. CRP No: 238/2009 dated 02-11-2009, relating to O P (Election) 20/2005 on the file of the Hon'ble Court of the Munsiff, Mavelikkaraġ2. 1161/ 2006 on the file of the Hon'ble Court of the Judicial First Class Magistrate, Kolancheryġ0 O.S.627/96 on the file of the Hon'ble Court of the Principal Sub Judge, Palakkadġ1. 304/06 on the file of the Hon'ble Court of the Munsiff, Hosdurgĩ S. 490/02 on the file of the Hon'ble Court of the First Addl. O S 565/03 on the file of the Hon'ble Court of Munsiff, Wadakkancherryħ. S T C 2586/05 on the file of the Hon'ble Court of the Judicial First Class Magistrate – II, MananthavadiĦ. 618/05 on the file of the Hon'ble Court of the III Addl. 116/02 on the file of the Hon'ble Court of the Judicial First Class Magistrate – I, KottarakaraĤ. C C 309/06 on the file of the Hon'ble Court of the Judicial First Class Magistrate I, Kochiģ. C C 113/02 on the file of the Hon'ble Court of the Judicial First Class Magistrate - I, KochiĢ. The report is supported by reason which can be given by a person who has knowledge in handwriting examination” Judgment dated 21-04-2009 in ST 2000/05 on the file of the Hon'ble Court of the Judicial First Class Magistrate -1, Kozhikode, Kerala.ġ. D1 I don’t find any suspicion on the capacity of the DW1 to give an expert opinion. “ Considering the mode of comparison made by DW-1 (K Khan Sahib) and the detailed report marked as Ext. Therefore, the concerned documents are forwarded herewith for favour of your consideration and analytical report It is thereafter that this court have identified your good self as the expert who could undertake the comparison work. On appeal the Hon'ble High Court of Kerala have directed this court to identify the expert who can probably effect a proper comparison on the same materials. 179/04 on the file of the Hon'ble Court of the Principal Sub Judge, Palakkad were returned from the State Finger Print Bureau, Thiruvananthapuram stating that a proper study could not be made on the disputed finger prints concerned in this case. Finally, we will discuss current efforts and future perspectives on the development of additional inhibitors of CRLs by targeting E2 and/or E3 of cullin neddylation and CRL-mediated ubiquitination as potential anti-cancer agents.Vide orders in S L P ( C ) no: 325/2010, the Hon'ble Supreme Court of India have upheld the judgment in the above case passed by the Hon'ble High Court of Kerala and refused to admit the S L P in which I had furnished Expert opinions in 8 finger print cases and 13 signature cases. ![]() We will further discuss how cullin neddylation controls CRL activity, and how CRLs are being validated as the attractive cancer targets by abrogating the RING component through genetic means and by inhibiting cullin neddylation via MLN4924, a small molecule indirect inhibitor of CRLs, currently in several Phase I clinical trials. In this review, we will introduce the UPS and CRL E3s and discuss the biological processes regulated by each of eight CRLs through substrate degradation. Activity of CRLs is dynamically regulated and requires the RING component and cullin neddylation. Cullin-RING Ligases (CRLs) with multiple components are the largest family of E3 ubiquitin ligases and are responsible for ubiquitination of ~20% of cellular proteins degraded through UPS. E3 ubiquitin ligases, particularly those known to be activated in human cancer, become an attractive choice. However, normal cell toxicity associated with bortezomib, resulting from global inhibition of protein degradation, promotes the focus of drug discovery efforts on targeting enzymes upstream of the proteasome for better specificity. Indeed, the FDA approval of bortezomib, the first class of general proteasome inhibitor, for the treatment of multiple myeloma, demonstrated that the UPS can be an attractive anti-cancer target. Thus, abnormal regulation of UPS disrupts the protein homeostasis and causes many human diseases, particularly cancer. The ubiquitin-proteasome system (UPS) promotes the timely degradation of short-lived proteins with key regulatory roles in a vast array of biological processes, such as cell cycle progression, oncogenesis and genome integrity.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |